We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+21.22%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$631M
AUM Growth
+$110M
Cap. Flow
+$37M
Cap. Flow %
5.86%
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17M
2
GKOS icon
Glaukos
GKOS
+$9.15M
3
BIIB icon
Biogen
BIIB
+$9.05M
4
ELGX
Endologix Inc
ELGX
+$6.78M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.67M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.1M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$11.1M
3
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$5.44M
4
BMY icon
Bristol-Myers Squibb
BMY
+$4.39M
5
CNC icon
Centene
CNC
+$4.18M

Sector Composition

Rank Sector Weight
1 Healthcare 92%
2 Financials 1.18%
3 Technology 0.15%
4 Energy 0.12%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
51
DexCom
DXCM
$32B
$4.82M 0.76%
227,600
-111,600
-33% -$2.18M
PTLA
52
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.73M 0.75%
120,805
– –
ENDP
53
DELISTED
Endo International plc
ENDP
$4.49M 0.71%
402,303
+102,103
+34% +$1.27M
RVNC
54
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.37M 0.69%
210,000
– –
UHS icon
55
Universal Health Services
UHS
$10.5B
$4.36M 0.69%
35,000
+5,000
+17% +$591K
RIGL icon
56
Rigel Pharmaceuticals
RIGL
$750M
$4.24M 0.67%
128,200
– –
NXTM
57
DELISTED
NxStage Medical Inc.
NXTM
$4.13M 0.65%
153,901
-5,000
-3% -$138K
OMCL icon
58
Omnicell
OMCL
$1.68B
$4.01M 0.63%
98,537
-20,000
-17% -$737K
AERI
59
DELISTED
Aerie Pharmaceuticals
AERI
$3.85M 0.61%
85,000
+50,000
+143% +$2.23M
KYNB
60
Kyntra Bio
KYNB
$29.4M
$3.81M 0.6%
6,174
+2,014
+48% +$1.23M
DVA icon
61
DaVita
DVA
$11.7B
$3.74M 0.59%
55,000
+10,000
+22% +$662K
WBA
62
DELISTED
Walgreens Boots Alliance
WBA
$3.74M 0.59%
45,000
+20,000
+80% +$1.68M
NBIX icon
63
Neurocrine Biosciences
NBIX
$16.6B
$3.68M 0.58%
85,000
+45,000
+113% +$1.93M
VTRS icon
64
Viatris
VTRS
$18.9B
$3.51M 0.56%
90,000
+80,000
+800% +$3.22M
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$3.39M 0.54%
30,000
+10,000
+50% +$1.17M
MGNX icon
66
MacroGenics
MGNX
$257M
$3.25M 0.52%
175,000
+20,000
+13% +$386K
ARRY
67
DELISTED
Array Biopharma Inc
ARRY
$3.13M 0.5%
350,000
-200,000
-36% -$2.13M
IMMU
68
DELISTED
Immunomedics Inc
IMMU
$3.1M 0.49%
+479,610
New +$2.43M
ACAD icon
69
Acadia Pharmaceuticals
ACAD
$5.03B
$3.09M 0.49%
90,000
+20,000
+29% +$706K
LH icon
70
Labcorp
LH
$25.9B
$3.09M 0.49%
25,084
-9,836
-28% -$1.16M
ISRG icon
71
Intuitive Surgical
ISRG
$134B
$3.07M 0.49%
+36,000
New +$2.84M
RDUS
72
DELISTED
Radius Health, Inc.
RDUS
$2.9M 0.46%
75,000
+20,000
+36% +$839K
TTPH
73
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.76M 0.44%
15,000
– –
ADMS
74
DELISTED
Adamas Pharmaceuticals
ADMS
$2.71M 0.43%
155,000
+25,000
+19% +$426K
KERX
75
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.62M 0.41%
425,111
– –
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rhenman & Partners Asset Management held 113 positions worth $631M, up 21% from $522M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management deployed $37M of net new capital in Q1 2017, opening 5 new positions and adding to 44 existing holdings. Its largest new stake was Abbott: 115,000 shares worth $5.11M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $4.39M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2017 buy was Abbott: 115,000 shares worth $5.11M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017, an estimated $17M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2017 reduction was Bristol-Myers Squibb, cutting an estimated $4.39M.
  • Rhenman & Partners Asset Management fully exited Teva Pharmaceuticals in Q1 2017, selling an estimated $13.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $631M portfolio in Q1 2017.
  • Rhenman & Partners Asset Management opened 5 new positions and closed 9 in Q1 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 21% quarter-over-quarter to $631M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2017, filed 19 Apr 2017.